Welcome to our dedicated page for Option Care Health news (Ticker: OPCH), a resource for investors and traders seeking the latest updates and insights on Option Care Health stock.
Option Care Health, Inc. (symbol: OPCH) is the largest independent provider of home and alternate site infusion services in the United States. With a dedicated team of over 7,500 members, including more than 4,500 clinicians, the company is at the forefront of delivering compassionate care to patients with acute and chronic conditions across all 50 states.
Formed from the merger of Option Care and BioScrip in August 2019, the company has successfully integrated its operations to create a unified national team. This merger has enabled Option Care Health to leverage its clinical leadership, extensive expertise, and national scale to reimagine the infusion care experience for patients, customers, and employees.
Option Care Health specializes in providing a variety of infusion therapies, including treatments for bleeding disorders, neurological conditions, heart failure, anti-infectives, and chronic inflammatory disorders. The company operates through home and alternate site settings, ensuring that patients receive care in a comfortable and convenient environment.
Recent achievements include strong financial performance, as highlighted in the company's third-quarter 2023 results. The CEO, John C. Rademacher, emphasized the outstanding clinical outcomes and extraordinary patient care that have contributed to these solid financial results. For the full year 2023, the company expects to generate substantial revenues and has provided updated financial guidance, reflecting its robust financial health.
The company's commitment to innovation is evident in its continuous efforts to elevate standards of care. Its clinical leadership and national scale allow Option Care Health to implement cutting-edge solutions that improve patient outcomes, reduce costs, and enhance the overall care experience.
Option Care Health's significant partnerships and collaborations further strengthen its market position. The company recently announced an increase in its share repurchase program authorization from $250 million to $500 million, demonstrating its confidence in its financial stability and future growth prospects.
For more information and the latest updates, please visit Option Care Health's Investor Relations page.
Option Care Health (NASDAQ: OPCH), the largest independent provider of home and alternate site infusion services in the U.S., will announce its first-quarter results for the period ending March 31, 2023, on May 4, 2023, prior to market opening.
Following this announcement, management will host a conference call at 8:30 a.m. ET to discuss the results. Interested parties can join by calling 800-445-7795 (U.S.) or 785-424-1699 (international), using conference ID “OPCH Q123.” A live audio webcast will also be available, along with a replay for on-demand listening shortly after the call.
With over 7,500 team members, including more than 4,500 clinicians, Option Care Health remains focused on enhancing patient care across all 50 states. For further details, visit OptionCareHealth.com.
Walgreens Boots Alliance (WBA) has sold approximately 15.5 million shares of Option Care Health (OPCH), raising funds at $30.75 per share. This includes 13.0 million shares in an underwritten secondary offering and a concurrent repurchase of 2.5 million shares by OPCH. Following the sale, WBA's ownership in OPCH decreased from 14% to 6%. The proceeds will primarily be allocated for debt paydown and to support WBA's strategic initiatives.
Option Care Health (NASDAQ: OPCH) announced a secondary offering of 13 million shares by an affiliate of Walgreens Boots Alliance, with no proceeds going to the company. Concurrently, Option Care plans to repurchase shares worth approximately $75 million from the selling stockholder, funded by cash on hand. The repurchase is contingent on the closing of the offering, which is underwritten by Goldman Sachs. The company emphasizes its role as the largest independent provider of home infusion services, catering to patients across 50 states.
Option Care Health (Nasdaq: OPCH) reported its financial results for Q4 and the full year 2022, showcasing a 10.8% increase in net revenue to $1,027.2 million compared to Q4 2021. Gross profit rose 8.9% to $231.1 million, representing 22.5% of revenue. However, net income fell to $47.5 million or $0.26 EPS, down from $75.5 million or $0.42 EPS a year prior. For the full year, net revenue grew 14.7% to $3,944.7 million, with net income of $150.6 million ($0.83 EPS). The company has authorized a $250 million share repurchase program and projects 2023 net revenue between $4.15 billion and $4.375 billion.
Option Care Health (NASDAQ: OPCH) will announce its Q4 and full-year results for 2022 on February 23, 2023, before the market opens. The company is the largest independent provider of home and alternate site infusion services in the U.S., employing over 7,500 team members, including 4,500 clinicians. A conference call to discuss these results is scheduled for 8:30 a.m. E.T. the same day. Participants can pre-register for the call or access it via a live audio webcast. A replay will be available shortly after the call for 90 days. For more information, visit OptionCareHealth.com.
Option Care Health, the largest independent provider of home and alternate site infusion services in the U.S., will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 9:00 AM PT in San Francisco. The CEO, John Rademacher, and CFO, Mike Shapiro, will present the company's insights and strategies. Interested parties can view the webcast and presentation materials on their official investor website. Option Care Health employs over 7,500 team members nationwide to enhance patient care.
Option Care Health Inc (NASDAQ: OPCH), the largest independent provider of home and alternate site infusion services, is expanding its partnership with WellSky. This collaboration aims to enhance the CareTend platform across 160+ infusion suites. With new automation, clinical decision support, and mobile capabilities, the partnership intends to improve patient outcomes and reduce costs. The initiative builds on over a decade of collaboration between the two companies, focusing on technology innovation in infusion therapy.
Option Care Health, the largest independent provider of home infusion services, reported Q3 2022 financial results with net revenue increasing 14.5% to $1,020.9 million from $891.9 million a year earlier. Gross profit rose 7.4% to $218.0 million, representing 21.4% of net revenue. Net income grew to $38.8 million, or $0.21 per share, up from $35.5 million a year ago. Adjusted EBITDA was $85.6 million, reflecting a 9.8% increase. The company also announced an acquisition of Rochester Home Infusion for $27.4 million. Guidance for 2022 is revised to $3.90 to $3.95 billion in revenue.
Option Care Health (NASDAQ: OPCH) will announce its Q3 2022 earnings on October 27, 2022, before the market opens. The management team will discuss the results in a conference call at 8:30 a.m. E.T. Pre-registration for the call is available, and a live audio webcast will be offered on their investor website. Option Care Health is the largest independent provider of home and alternate site infusion services in the U.S., serving patients in all 50 states with over 7,000 team members, including more than 4,000 clinicians.
Walgreens Boots Alliance (WBA) has sold 11 million shares of Option Care Health (OPCH) in a secondary offering, reducing its ownership from 20.5% to 14.4%. The proceeds will primarily be utilized for debt paydown and to support strategic priorities. CEO Rosalind Brewer emphasized the action aligns with the company's strategy and enhances balance sheet flexibility. Walgreens Boots Alliance continues to serve millions through over 13,000 locations worldwide, aiming to improve healthcare access.
FAQ
What is the current stock price of Option Care Health (OPCH)?
What is the market cap of Option Care Health (OPCH)?
What services does Option Care Health provide?
How many states does Option Care Health operate in?
Who are the key team members at Option Care Health?
What recent financial achievements has Option Care Health reported?
What was the impact of the merger between Option Care and BioScrip?
How does Option Care Health ensure quality care?
What is the focus of Option Care Health's innovation?
What is Option Care Health's share repurchase program?
Where can investors find more information about Option Care Health?
How can patients receive care from Option Care Health?
